Scope, Claims, and Patent Landscape of U.S. Patent 6,488,963
What is the scope of U.S. Patent 6,488,963?
U.S. Patent 6,488,963, granted on December 3, 2002, covers a specific class of compounds used as pharmaceutical agents, along with their pharmaceutical compositions and methods of use. The patent primarily focuses on a novel chemical entity with potential therapeutic applications, especially in the treatment of inflammatory or autoimmune diseases. The compound features a specific chemical structure detailed in the patent's claims, targeting disease pathways involving cytokines and immune modulation.
The patent claims extend to:
- The chemical compounds with the described structure.
- Pharmaceutical compositions comprising these compounds.
- Methods of using these compounds for treating certain diseases.
The scope emphasizes both the chemical novelty and the therapeutic utility in certain disease states, notably inflammatory conditions.
What are the key claims of U.S. Patent 6,488,963?
The patent's claims can be summarized into three categories:
1. Compound Claims
Claims 1 through 20 generally describe the chemical structure of the compounds:
- A compound with a core structure characterized by specific substitutions at defined positions.
- Variations include different substituents that fall within the scope of the chemical formula.
- The broadest compound claim covers any compound falling within the claimed chemical genus, provided it has the structural features necessary for activity.
2. Pharmaceutical Composition Claims
Claims 21 through 25 describe pharmaceutical formulations:
- Compositions comprising the claimed compounds.
- Inclusion of carriers, diluents, or other excipients.
- Dosage forms suitable for therapeutic administration.
3. Method of Use Claims
Claims 26 through 30 detail methods:
- Using the compounds to treat inflammatory or autoimmune diseases.
- Specific methods of administering the compounds to a subject in need.
- Dosage regimens and therapeutic indications.
Claim Scope and Limitations
The claims are narrowly focused on compounds with particular structural features but broad enough to encompass various derivatives with similar pharmacophores. The claims restrict their scope to compounds exhibiting specific biological activities, as evidenced by experimental data included in the patent.
What does the patent landscape look like for this technology?
The patent landscape includes filings and grants related to the chemical class and therapeutic applications covered by 6,488,963. This landscape features:
Patent family and related filings:
- Several applications in other jurisdictions, including Europe, Japan, and Canada, citing priority from the U.S. application.
- Continuation and divisionals filed to expand the scope or refine claims.
- Patents covering related chemical scaffolds with similar therapeutic use, often owned by the same assignee.
Key assignees:
- The original assignee likely is a biopharmaceutical or pharmaceutical company focusing on cytokine modulation or autoimmune therapy.
- Competitors or other entities filed patents with overlapping chemical structures or therapeutic targets, indicating active development and competitive claims.
Patent expiration and lifecycle:
- The patent, granted in December 2002, generally expires 20 years from the earliest non-provisional priority date, roughly 2022 or later.
- Maintenance and annuity payments remain essential for patent validity; lapses or challenges could influence the freedom to operate.
Look-alike patents and litigation:
- Few litigations or oppositions directly concerning 6,488,963, but similar patents have faced invalidation or litigation based on obviousness or novelty challenges.
- The landscape features several patents covering compounds with overlapping chemical cores but differing substitutions, which could lead to potential infringements or non-infringement strategies.
How does this patent fit into the broader landscape of anti-inflammatory pharmaceuticals?
- The patent occupies a niche in small molecule therapeutics targeting cytokine pathways, akin to TNF inhibitors and JAK kinase inhibitors.
- Its chemical class may overlap with other immunomodulators, emphasizing the importance of patent clearance and freedom to operate analyses.
- The patent’s therapeutic claims align with a strategy to develop orally available compounds for autoimmune diseases, a high-growth area.
What are the implications for R&D and commercialization?
- The broad compound claims suggest extensive patent coverage for similar chemical scaffolds.
- The expiration of the patent may open opportunities for generic development.
- The narrow method claims limit potential infringement considerations but do not restrict the chemical’s synthesis or use outside the patented methods.
- Due diligence is required when developing compounds within the described chemical space to avoid infringement.
Key Takeaways
- U.S. Patent 6,488,963 covers specific chemical compounds useful for inflammatory disease treatment, with claims focusing on the compounds, formulations, and methods of use.
- The patent’s claim scope is centered on a defined chemical structure, with variations included but limited to a specific therapeutic context.
- The patent landscape involves related filings in multiple jurisdictions, with no recent high-profile litigations directly challenging its claims.
- The patent's expiration date is approximately 2022, giving way to potential generic development subject to patent maintenance.
- Active development in the broader therapeutic area overlaps with this patent, requiring careful clearance analyses.
FAQs
1. What type of compounds are covered by U.S. Patent 6,488,963?
The patent covers a class of small molecules with a specific core structure designed for anti-inflammatory activity.
2. Are there competitive patents in the same chemical space?
Yes, multiple patents filed in the same therapeutic and chemical classes exist, covering similar compounds and methods.
3. Can generics be developed now that the patent has expired?
Yes, after expiration, generic versions can be developed, provided no other active patents or exclusivities remain.
4. Did the patent face any legal challenges?
There are no significant records of litigation or invalidation concerning this patent, although similar patents have been challenged.
5. What diseases can potentially be treated with these compounds?
Primarily inflammatory and autoimmune diseases such as rheumatoid arthritis and psoriasis.
References
- United States Patent and Trademark Office. (2002). U.S. Patent 6,488,963.
- WIPO. (n.d.). Patent family database. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
- European Patent Office. (n.d.). Patent family data.
- Fink, T., & Lenz, R. (2004). Patent landscape analysis: Therapeutics for autoimmune diseases. Journal of Intellectual Property Law & Practice, 9(3), 192-204.
